Cystic Fibrosis in Adults

Current and Future Management Strategies

Brian M Morrissey, Bettina C. Schock, Gregory P. Marelich, Carroll E Cross

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Over 30,000 individuals in the United States of America are living with cystic fibrosis (CF). Despite incremental advances in care and understanding of its pathophysiology, CF remains a significantly life-limiting disease. Readily accessible newborn screening, genetic testing, and an improved awareness have increased the early recognition of CF, atypical presentations of CF, and the CF-related diseases. Improvements in medical management have led to continually improving life expectancy for patients with CF. Despite improved management strategies, severe lung disease remains the commonly life-limiting pathology. We review the pathophysiology, diagnosis, and management of the respiratory-tract manifestations of CF that represent the life-limiting aspects of the condition and summarize upcoming and possible future therapies for patients with CF.

Original languageEnglish (US)
Pages (from-to)275-287
Number of pages13
JournalClinical Reviews in Allergy and Immunology
Volume25
Issue number3
DOIs
StatePublished - Dec 2003

Fingerprint

Cystic Fibrosis
Genetic Testing
Life Expectancy
Respiratory System
Lung Diseases
Newborn Infant
Pathology

Keywords

  • Adult
  • CF
  • CFTR
  • Cystic fibrosis

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Cystic Fibrosis in Adults : Current and Future Management Strategies. / Morrissey, Brian M; Schock, Bettina C.; Marelich, Gregory P.; Cross, Carroll E.

In: Clinical Reviews in Allergy and Immunology, Vol. 25, No. 3, 12.2003, p. 275-287.

Research output: Contribution to journalArticle

@article{2267ffebc691486f871f03fec52d5671,
title = "Cystic Fibrosis in Adults: Current and Future Management Strategies",
abstract = "Over 30,000 individuals in the United States of America are living with cystic fibrosis (CF). Despite incremental advances in care and understanding of its pathophysiology, CF remains a significantly life-limiting disease. Readily accessible newborn screening, genetic testing, and an improved awareness have increased the early recognition of CF, atypical presentations of CF, and the CF-related diseases. Improvements in medical management have led to continually improving life expectancy for patients with CF. Despite improved management strategies, severe lung disease remains the commonly life-limiting pathology. We review the pathophysiology, diagnosis, and management of the respiratory-tract manifestations of CF that represent the life-limiting aspects of the condition and summarize upcoming and possible future therapies for patients with CF.",
keywords = "Adult, CF, CFTR, Cystic fibrosis",
author = "Morrissey, {Brian M} and Schock, {Bettina C.} and Marelich, {Gregory P.} and Cross, {Carroll E}",
year = "2003",
month = "12",
doi = "10.1385/CRIAI:25:3:275",
language = "English (US)",
volume = "25",
pages = "275--287",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Cystic Fibrosis in Adults

T2 - Current and Future Management Strategies

AU - Morrissey, Brian M

AU - Schock, Bettina C.

AU - Marelich, Gregory P.

AU - Cross, Carroll E

PY - 2003/12

Y1 - 2003/12

N2 - Over 30,000 individuals in the United States of America are living with cystic fibrosis (CF). Despite incremental advances in care and understanding of its pathophysiology, CF remains a significantly life-limiting disease. Readily accessible newborn screening, genetic testing, and an improved awareness have increased the early recognition of CF, atypical presentations of CF, and the CF-related diseases. Improvements in medical management have led to continually improving life expectancy for patients with CF. Despite improved management strategies, severe lung disease remains the commonly life-limiting pathology. We review the pathophysiology, diagnosis, and management of the respiratory-tract manifestations of CF that represent the life-limiting aspects of the condition and summarize upcoming and possible future therapies for patients with CF.

AB - Over 30,000 individuals in the United States of America are living with cystic fibrosis (CF). Despite incremental advances in care and understanding of its pathophysiology, CF remains a significantly life-limiting disease. Readily accessible newborn screening, genetic testing, and an improved awareness have increased the early recognition of CF, atypical presentations of CF, and the CF-related diseases. Improvements in medical management have led to continually improving life expectancy for patients with CF. Despite improved management strategies, severe lung disease remains the commonly life-limiting pathology. We review the pathophysiology, diagnosis, and management of the respiratory-tract manifestations of CF that represent the life-limiting aspects of the condition and summarize upcoming and possible future therapies for patients with CF.

KW - Adult

KW - CF

KW - CFTR

KW - Cystic fibrosis

UR - http://www.scopus.com/inward/record.url?scp=1242306683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242306683&partnerID=8YFLogxK

U2 - 10.1385/CRIAI:25:3:275

DO - 10.1385/CRIAI:25:3:275

M3 - Article

VL - 25

SP - 275

EP - 287

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 3

ER -